DENND2A

Across TCGA pan-cancer cohorts, DENND2A RNA differs between tumor and matched normal tissue in 15 of 18 cancer types tested, making tumor–normal expression one of DENND2A’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where DENND2A RNA is repressed in tumor relative to normal tissue. In most cancer types DENND2A is over-expressed in tumor, although a few such as BLCA and COAD show the opposite, repressed pattern.

BLCA, COAD, and THCA are the cancer types where DENND2A tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in DENND2A RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	Male	IV	−3.014	<.001	11	view →
COAD	Male	IV	−1.430	<.001	11	view →
THCA	All	II,III,IV	−0.795	<.001	10	view →
KICH	Female	II,III,IV	−2.531	<.001	9	view →
LUAD	Female	III,IV	−1.685	<.001	9	view →
LUSC	Female	II,III,IV	−2.641	<.001	8	view →
KIRP	Male	All	−1.940	<.001	7	view →
UCEC	All	III,IV	−3.057	<.001	6	view →
BRCA	All	II,III,IV	−1.856	<.001	6	view →
KIRC	Male	II,III,IV	−1.126	<.001	6	view →
HNSC	Female	IV	+1.148	.018	4	view →
READ	All	All	−1.148	.001	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 15 lineages.

DENND2A–BLCA

Open the BLCA breakdown →